Brought to you by 
Ocera Therapeutics gets $35.5mm through its Series C
06 Mar 2008
Executive Summary
Ocera Therapeutics (gastrointestinal and liver disease compounds) has raised $35.5mm through the closing of its Series C venture round. Lead investor Montagu Newhall Associates was joined by other new backers InterWest Partners, AgeChem Venture Fund, Cross Creek Capital (an affiliate of Wasatch Advisors), FinTech, and CDIB BioScience. Current shareholders Domain Associates, Sofinnova Ventures, and Thomas, McNerney & Partners also participated. A representative from InterWest Partners will take a seat on the company's board.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ocera Therapeutics gets $35.5mm through its Series C
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice